| Jun 20 |
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval
|
| Jun 20 |
Sarepta Duchenne gene therapy wins broader use from FDA
|
| Jun 17 |
Sarepta Therapeutics: Navigating Elevidys Upside Potential
|
| Jun 13 |
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
|
| Jun 13 |
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
|
| Jun 13 |
Sarepta gains after Pfizer’s late-stage setback for Duchenne therapy
|
| Jun 13 |
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
|
| Jun 6 |
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
|
| May 31 |
Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
|
| May 30 |
Sarepta Therapeutics set to join S&P MidCap 400
|
